Get started
VVV

Virax Biolabs Group Limited

No trades
No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonals
Full chart
Full chart

Compare with Virax Biolabs Group Limited



Key stats


Market capitalization
‪3.11 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−16.91 USD
Net income (FY)
‪−5.02 M‬ USD
Revenue (FY)
‪12.42 K‬ USD
Shares float
‪792.03 K‬
Beta (1Y)
3.15

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
26
Change (1Y)
+7+36.84%
Revenue / Employee (1Y)
477.81 USD
Net income / Employee (1Y)
‪−193.22 K‬ USD

Profile


Sector
Finance
Industry
Financial Conglomerates
CEO
James Foster
Website
viraxbiolabs.com
Headquarters
Lanarkshire
Founded
2013
IPO date
Jul 21, 2022
ISIN
KYG9495L1335
CUSIP
G9495L133
FIGI
BBG0166WT3L7
Identifiers
ISIN KYG9495L1335
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The company was founded by James Foster and Cameron Shaw in 2013 and is headquartered in London, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently asked questions


The current price of VRAX is 3.79 USD — it has decreased by −2.82% in the past 24 hours. Watch Virax Biolabs Group Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Virax Biolabs Group Limited stocks are traded under the ticker VRAX.
VRAX stock has fallen by −22.97% compared to the previous week, the month change is a −5.25% fall, over the last year Virax Biolabs Group Limited has showed a −84.04% decrease.
VRAX reached its all-time high on Jul 29, 2022 with the price of 7,250.00 USD, and its all-time low was 2.50 USD and was reached on Apr 10, 2026. View more price dynamics on VRAX chart.
See other stocks reaching their highest and lowest prices.
VRAX stock is 10.80% volatile and has beta coefficient of 3.15. Track Virax Biolabs Group Limited stock price on the chart and check out the list of the most volatile stocks — is Virax Biolabs Group Limited there?
Today Virax Biolabs Group Limited has the market capitalization of ‪3.11 M‬, it has decreased by −18.81% over the last week.
Yes, you can track Virax Biolabs Group Limited financials in yearly and quarterly reports right on TradingView.
Virax Biolabs Group Limited is going to release the next earnings report on Dec 2, 2026. Keep track of upcoming events with our Earnings Calendar.
VRAX net income for the last half-year is ‪−2.68 M‬ USD, while the previous report showed ‪−2.34 M‬ USD of net income which accounts for 0.00% change. Track more Virax Biolabs Group Limited financial stats to get the full picture.
No, VRAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 18, 2026, the company has 26 employees. See our rating of the largest employees — is Virax Biolabs Group Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Virax Biolabs Group Limited EBITDA is ‪−5.96 M‬ USD, and current EBITDA margin is ‪−47.98 K‬%. See more stats in Virax Biolabs Group Limited financial statements.
Like other stocks, VRAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Virax Biolabs Group Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Virax Biolabs Group Limited technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Virax Biolabs Group Limited stock shows the sell signal. See more of Virax Biolabs Group Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.